Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PADD: Peginterferon alfa-2b Add-on in HBeAg-positive Chronic Hepatitis B
NCT00883844Phase 4Completed
- Sponsor
- Foundation for Liver Research
- Start
- Apr 2009
- Primary completion
- Jun 2012
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of peginterferon alfa-2b in Chronic Hepatitis B (CHB) (2 arms), sponsored by Foundation for Liver Research. Primary endpoint: HBeAg loss and HBV DNA < 200 IU/mL at 72 weeks. Started Apr 2009; status: completed.
02
Drugs
peginterferon alfa-2b
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT00883844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00883844.